

Press release for immediate release

Genomtec files a new patent application in the UK

Wroclaw, Poland - November 29, 2021. - Genomtec S.A. "GMT", a NewConnect-listed medtech company specializing in the development of advanced technology in the area of point-of-care (POC) genetic diagnostics, has filed a patent application entitled "Thermal interface arrangement" for a proprietary method of heat transfer and measurement with the UK Intellectual Property Office (UK IPO). The Issuer's invention may have broad application not only in diagnostics, but also in biomedical solutions, electronics or mechanics.

- Royalties from the potential use of patent-protected inventions or the sale of licenses are a possible source of revenue for the Company. Today Genomtec already holds 6 granted patents for its proprietary technological solutions, which can be used not only in genetic diagnostics, but also in other industries, an example of which is the invention just submitted for protection – said Miron Tokarski, co-founder and CEO of Genomtec.

The described patent application enhances Genomtec's intellectual property, competitive advantage, and uniqueness our diagnostic solutions.

#####

Additional information at:

Genomtec S.A.
Magdalena Kicińska
+48 604 201 230
m.kicinska@genomtec.com

About Genomtec:

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT[®] isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec[®] SARS-CoV-2 EvaGreen[®] laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.



Genomtec was founded in 2016. Genomtec SA is headquartered in Wrocław.

More information at: www.genomtec.com Genomtec została założona w 2016 r. Siedziba Spółki Genomtec SA znajduje się we Wrocławiu.

Więcej informacji: www.genomtec.com